Holocene Advisors Boosts Stake in Repligen Corporation

Institutional investor increases position in biotech company by 47% in Q3

Mar. 16, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Holocene Advisors LP, an institutional investor, increased its stake in Repligen Corporation (NASDAQ:RGEN) by 47% in the third quarter of 2026, according to a recent SEC filing. Holocene Advisors now owns 1,377,104 shares of the biotechnology company's stock, representing about 2.45% of Repligen's outstanding shares.

Why it matters

Repligen is a leading manufacturer of critical bioproduction consumables used in the development and manufacturing of biopharmaceuticals. Holocene Advisors' increased stake suggests the institutional investor sees strong growth potential for Repligen as the demand for its products continues to rise in the booming biotech industry.

The details

According to the SEC filing, Holocene Advisors purchased an additional 440,290 shares of Repligen in the third quarter, bringing its total position to 1,377,104 shares. This represents about a 47% increase in Holocene's stake in the company. Repligen's stock closed at $114.20 per share on Monday, giving Holocene's position a market value of around $184 million.

  • Holocene Advisors increased its stake in Repligen in the 3rd quarter of 2026.

The players

Holocene Advisors LP

An institutional investment firm that has increased its stake in Repligen Corporation.

Repligen Corporation

A biotechnology company that develops and manufactures high-value consumable products for bioprocessing applications.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Holocene Advisors' increased investment in Repligen signals the firm's confidence in the biotech company's growth prospects as demand for its critical bioproduction consumables continues to rise. This highlights the strong performance and market position of Repligen within the booming biotechnology industry.